Following the political coup that took place in Mali in 2012, there was a significant migration of Malians into Niger. It was estimated that more than 50,000 Malians took refuge in the country, settling primarily in the border regions. This migration increased the likelihood of cross-border transmission of NTDs among refugees coming from Mali. Recognizing the risk this posed, the END Fund approached Helen Keller International (HKI) about the NTD treatment for Malian refugees living in camps in the border regions.
END Fund Investment
The END Fund partnered with HKI, who worked alongside the United Nations Refugee Agency (UNHCR), as well as Niger’s Ministry of Health (MoH) and Ministry of Interior to deliver treatment in refugee camps for intestinal worms, schistosomiasis, LF and trachoma.
Program to Date
The program provided treatment to over 29,000 individuals for at least one NTD. In addition, the program conducted a trachoma prevalence survey among the refugee camps and provided treatment in highly endemic areas. Overall, the program achieved good coverage rates, considering the mobility of the population that it aimed to treat. The program also provided valuable insight into the flexible approach required to successfully implement mass drug administrations (MDAs) in an emergency context.